MORRIS PLAINS, N.J.,
Oct. 1, 2015 /PRNewswire/ --
Xybion Corporation announced today that Novo Nordisk (NYSE: NVO)
has selected Xybion's Pristima® Suite to manage all its non-GLP
pharmacology studies in a global setting. The Pristima Suite is a
preclinical software platform that offers a fully integrated,
end-to-end enterprise solution for tracking and managing veterinary
facilities and animal studies throughout the preclinical research
process.
Xybion will provide a number of services and improvements to the
Pristima platform to support non-GLP pharmacology studies, enabling
Novo Nordisk to leverage the system for early drug discovery
studies. In addition, Xybion will provide critical training and
implementation services to configure Pristima and prepare the user
community to meet Novo Nordisk best practices and reporting
specifications.
Dr. Pradip Banerjee, CEO at
Xybion stated, "Xybion is delighted to welcome Novo Nordisk to our
client community; this opens yet another chapter in the Pristima
history and is a further testament to the configurability that our
engineers have built into the product. Our strategies facilitate
scientists' research activities, improve their efficiency and
ensure the quality of their findings. I am excited that this
project provides an for an additive set of functions targeted
directly at the pharmacology teams of our pharmaceutical clients
and further expands the integrative value that Xybion and Pristima
bring to the market."
Carlos Frade, VP of Preclinical
R&D Solutions at Xybion commented, "After a diligent assessment
in which Novo Nordisk and Xybion analyzed the approaches by which
Pristima supports the operational planning, the data collection,
the data evaluation, the instrument interfacing and efficiency
improvements provided by Pristima, I am confident that we are
delivering the best enterprise solution for drug discovery teams
all over the world."
ABOUT XYBION
Xybion is a leading provider of software, services and consulting
for global corporations operating in highly regulated
industries. Our unique solutions focus on integrated
preclinical lab management, early-stage drug discovery, regulatory
compliance, GRC, quality management and systems validation.
Xybion's combination of software, business process management,
services, validation and staffing enables us to cover a broad
spectrum of critical business needs for companies and we deliver
our solutions on global scale. Our leadership in this dynamic
and ever-changing industry has been a cornerstone of our high-value
reputation. To learn more, please visit www.xybion.com.
About Pristima
The Pristima® Suite is a fully integrated, end-to-end
enterprise solution for tracking and managing veterinary facilities
and research subjects throughout the preclinical research process.
From ordering through the study submission process,
the Pristima software platform delivers essential capabilities
across the entire drug discovery process. The system
enables organizations to maintain all preclinical data in one
system, from compound receipt through dossier submission and slide
archival. For over 35 years, global
pharmaceutical companies and CROs have relied on
Xybion to drive data management while ensuring quality,
efficiency, and compliance.
CONTACT: Kevin Miller,
877-617-9700
Logo - http://photos.prnewswire.com/prnh/20150930/272633LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/xybion-announces-that-novo-nordisk-selects-pristima-to-manage-pharmacology-research-studies-across-all-research-sites-300152574.html
SOURCE Xybion